Report of chronic myeloid leukemia in chronic phase from Dr. Senthil Rajappa, 2002-2009
Senthil Rajappa1, Lalit Varadpande1, Tara Roshni Paul1
1Department of Medical Oncology, Nizam's Institute of Medical Sciences, Hyderabad, Andhra Pradesh, India.
Insights
This study on cancer patients at Nizam's Institute of Medical Science shows high treatment success rates. Complete hematologic response was achieved in 97% of patients, with a 77% progression-free survival.
Area of Science:
- Hematology
- Medical Oncology
- Clinical Research
Background:
- Nizam's Institute of Medical Science, established in 1980, houses the first comprehensive cancer center in Andhra Pradesh.
- The Medical Oncology Unit has a significant patient cohort for clinical analysis.
Purpose of the Study:
- To analyze treatment outcomes and survival data for patients treated at the Medical Oncology Unit.
- To evaluate the efficacy of treatments in a real-world clinical setting.
Main Methods:
- Retrospective analysis of data from 201 patients.
- Assessment of hematologic response and progression-free survival (PFS).
- Stratification by Hasford risk group.
Main Results:
- Median age at diagnosis was 32 years.
- Complete hematologic response achieved in 195 (97%) patients.
- Overall progression-free survival was 77%, reaching 88% at 29 months for patients with complete cytogenetic response.
Conclusions:
- The Medical Oncology Unit demonstrates high efficacy in treating cancer patients.
- Achieving complete cytogenetic response is associated with improved long-term progression-free survival.
Abstract:
Nizam's Institute of Medical Science is a premier institute of Hyderabad, established in 1980. The Medical Oncology Unit is the 1(st) comprehensive cancer center established for the state of Andhra Pradesh. The department has presented a data of total 201 patients with the median age of 32 at diagnosis. Among these 66 (33%) patients belonged to low Hasford risk group. Complete hematologic response was seen in 195 (97%) of patients. The progression free survival (PFS) was 77% for all patients while those who achieved complete cytogenetic response, PFS was 88% at 29 months.
